Bridging Analyses: The Role of Cost Per Event A...

By João L. Carapinha

March 17, 2026

This editorial by Petrou et al., published in the Journal of Medical Economics, critiques escalating pharmaceutical expenditures amid new therapies like glucag...
EU Medicines Regulation Achievements: EMA’s 2025 Highlights and Future ...
Quantifying Cancer Productivity Losses in Europe: Economic Impact Analysis
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
FDA Biosimilar Approval Reforms: Accelerating Access and Reducing Drug Costs
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...